0001193125-17-360246.txt : 20171204 0001193125-17-360246.hdr.sgml : 20171204 20171204161832 ACCESSION NUMBER: 0001193125-17-360246 CONFORMED SUBMISSION TYPE: 425 PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20171204 DATE AS OF CHANGE: 20171204 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: AETNA INC /PA/ CENTRAL INDEX KEY: 0001122304 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] IRS NUMBER: 232229683 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 425 SEC ACT: 1934 Act SEC FILE NUMBER: 001-16095 FILM NUMBER: 171237252 BUSINESS ADDRESS: STREET 1: 151 FARMINGTON AVENUE CITY: HARTFORD STATE: CT ZIP: 06156 BUSINESS PHONE: 8602730123 MAIL ADDRESS: STREET 1: 151 FARMINGTON AVENUE CITY: HARTFORD STATE: CT ZIP: 06156 FORMER COMPANY: FORMER CONFORMED NAME: AETNA U S HEALTHCARE INC DATE OF NAME CHANGE: 20000822 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: CVS HEALTH Corp CENTRAL INDEX KEY: 0000064803 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] IRS NUMBER: 050494040 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 425 BUSINESS ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 BUSINESS PHONE: 4017651500 MAIL ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 FORMER COMPANY: FORMER CONFORMED NAME: CVS CAREMARK CORP DATE OF NAME CHANGE: 20070509 FORMER COMPANY: FORMER CONFORMED NAME: CVS/CAREMARK CORP DATE OF NAME CHANGE: 20070322 FORMER COMPANY: FORMER CONFORMED NAME: CVS CORP DATE OF NAME CHANGE: 19970128 425 1 d505652d425.htm 425 425

Filed by CVS Health Corporation

Pursuant to Rule 425 under the Securities Act of 1933

And deemed filed pursuant to Rule 14a-12

Under the Securities Exchange Act of 1934

Subject Company: Aetna Inc.

Commission File No.: 001-16095

Date: December 4, 2017

 

LOGO

CVS HEALTH ACQUISITION OF AETNA CREATES LEADING INTEGRATED HEALTH CARE PLATFORM TO DELIVER BETTER CARE AT LOWER COST

 

CVS Health (NYSE: CVS)1    Aetna (NYSE: AET)
   

●     ~30,000 clinicians and lower-cost sites of care, including 1,100 MinuteClinic locations

   

●     22.2M medical members1 across the U.S. and other locations

   

●     Pharmacy Advisor and other clinical programs provide rich pharmacy data that can drive better treatment adherence and insights

   

●     Robust provider networks and healthcare services to improve patient outcomes across the care continuum

   

●     Vast consumer touch points, with >70% of U.S. population living within 3 miles of a CVS Pharmacy location

   

●     National health insurance benefit platform can identify and target members to manage large commercial and government books; >$44B in FY 2016 medical costs

 

   

●     Headquarters: Woonsocket, RI

   

●     Headquarters: Hartford, CT

●     Leadership: Larry Merlo, President & CEO

   

●     Leadership: Mark Bertolini, Chairman & CEO

●     Employees: 250,000

   

●     Employees: 49,500

●     2016 Revenue: $177.5B

 

   

●     2016 Revenue: $63.2B

 

 

Pro Forma Financials2 ($, billions): Revenue: 221.4; Adj. EBITDA: 18.5; % Margin: 8.4%

 

TRANSACTION OVERVIEW

 

●   Equity value of $69 billion; $77 billion transaction value including the assumption of Aetna’s debt
●   Approximately $207 per AET share in cash and stock, comprised of $145 per share in cash and 0.8378 in CVS shares per AET share3
●   CVS and AET shareholders will own 78% and 22% of combined company, respectively
●   Expect transaction to close in the second half of 2018
●   Subject to approval by CVS and AET shareholders, regulatory approvals and other customary closing conditions

VALUE CREATION HIGHLIGHTS

 

●   Enhanced competitive positioning
●   Low- to mid-single accretion in the second full year after close
●   Ability to deliver $750 million in near-term synergies; potential to deliver significant incremental value over the long-term
●   Potential to generate significant new growth opportunities

GOVERNANCE

 

●   Three Aetna directors, including Aetna Chairman and CEO Mark Bertolini, to be added to the CVS Health Board of Directors at closing
●   Members of Aetna management team to play significant roles in the combined company
●   Aetna will operate as stand-alone business unit of CVS Health led by members of the current management team

 

 

1 Data as of September 30, 2017.

2 Pro forma financials trailing 12 months through September 30, 2017.

3 Based on 5-Day Volume Weighted Average Price ending December 1, 2017, of $74.21 per share.

LOGO

No Offer or Solicitation

This communication is for informational purposes only and not intended to and does not constitute an offer to subscribe for, buy or sell, the solicitation of an offer to subscribe for, buy or sell or an invitation to subscribe for, buy or sell any securities or the solicitation of any vote or approval in any jurisdiction pursuant to or in connection with the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law.

Additional Information and Where to Find It

In connection with the proposed transaction between CVS Health Corporation (“CVS Health”) and Aetna Inc. (“Aetna”), CVS Health and Aetna will file relevant materials with the Securities and Exchange Commission (the “SEC”), including a CVS Health registration statement on Form S-4 that will include a joint proxy statement of CVS Health and Aetna that also constitutes a prospectus of CVS Health, and a definitive joint proxy statement/prospectus will be mailed to stockholders of CVS Health and shareholders of Aetna. INVESTORS AND SECURITY HOLDERS OF CVS HEALTH AND AETNA ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the registration statement and the joint proxy statement/prospectus (when available) and other documents filed with the SEC by CVS Health or Aetna through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by CVS Health will be available free of charge within the Investors section of CVS Health’s Web site at http://www.cvshealth.com/investors or by contacting CVS Health’s Investor Relations Department at 800-201-0938. Copies of the documents filed with the SEC by Aetna will be available free of charge on Aetna’s internet website at http://www.Aetna.com or by contacting Aetna’s Investor Relations Department at 860-273-8204.

Participants in Solicitation

CVS Health, Aetna, their respective directors and certain of their respective executive officers may be considered participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of CVS Health is set forth in its Annual Report on Form 10-K for the year ended December 31, 2016 (“CVS Health’s Annual Report”), which was filed with the SEC on February 9, 2017, its proxy statement for its 2017 annual meeting of stockholders, which was filed with the SEC on March 31, 2017, and its Current Report on Form 8-K, which was filed with the SEC on May 12, 2017. Information about the directors and executive officers of Aetna is set forth in its Annual Report on Form 10-K for the year ended December 31, 2016 (“Aetna’s Annual Report”), which was filed with the SEC on February 17, 2017, its proxy statement for its 2017 annual meeting of shareholders, which was filed with the SEC on April 7, 2017, and its Current Reports on Form 8-K, which were filed with the SEC on May 24, 2017 and October 2, 2017. Other information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus and other relevant materials to be filed with the SEC when they become available.

Cautionary Statement Regarding Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 (the “Reform Act”) provides a safe harbor for forward-looking statements made by or on behalf of CVS Health or Aetna. This communication may contain forward-looking statements within the meaning of the Reform Act. You can generally identify forward-looking statements by the use of forward-looking terminology such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “evaluate,” “expect,” “explore,” “forecast,” “guidance,” “intend,” “likely,” “may,” “might,” “outlook,” “plan,” “potential,” “predict,” “probable,” “project,” “seek,” “should,” “view,” or “will,” or the negative thereof or other variations thereon or comparable terminology. These forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond CVS Health’s and Aetna’s control.

Statements in this communication regarding CVS Health and Aetna that are forward-looking, including CVS Health’s and Aetna’s projections as to the closing date for the pending acquisition of Aetna (the “transaction”), the extent of, and the time necessary to obtain, the regulatory approvals required for the transaction, the anticipated benefits of the transaction, the impact of the transaction on CVS Health’s and Aetna’s businesses, the expected terms and scope of the expected financing for the transaction, the ownership percentages of CVS Health’s common stock of CVS Health stockholders and Aetna shareholders at closing, the aggregate amount of indebtedness of CVS Health following the closing of the transaction, CVS Health’s expectations regarding debt repayment and its debt to capital ratio following the closing of the transaction, CVS Health’s and Aetna’s respective share repurchase programs and ability and intent to declare future dividend payments, the number of prescriptions used by people served by the combined companies’ pharmacy benefit business, the synergies from the transaction, and CVS Health’s, Aetna’s and/or the combined company’s future operating results, are based on CVS Health’s and Aetna’s managements’ estimates, assumptions and projections, and are subject to significant uncertainties and other factors, many of which are beyond their control. In particular, projected financial information for the combined businesses of CVS Health and Aetna is based on estimates, assumptions and projections and has not been prepared in conformance with the applicable accounting requirements of Regulation S-X relating to pro forma financial information, and the required pro forma adjustments have not been applied and are not reflected therein. None of this information should be considered in isolation from, or as a substitute for, the historical financial statements of CVS Health and Aetna. Important risk factors related to the transaction could cause actual future results and other future events to differ materially from those currently estimated by management, including, but not limited to: the timing to consummate the proposed transaction; the risk that a regulatory approval that may be required for the proposed transaction is delayed, is not obtained or is obtained subject to conditions that are not anticipated; the risk that a condition to the closing of the proposed transaction may not be satisfied; the ability to achieve the synergies and value creation contemplated; CVS Health’s ability to promptly and effectively integrate Aetna’s businesses; and the diversion of and attention of management of both CVS Health and Aetna on transaction-related issues.

In addition, this communication may contain forward-looking statements regarding CVS Health’s or Aetna’s respective businesses, financial condition and results of operations. These forward-looking statements also involve risks, uncertainties and assumptions, some of which may not be presently known to CVS Health or Aetna or that they currently believe to be immaterial also may cause CVS Health’s or Aetna’s actual results to differ materially from those expressed in the forward-looking statements, adversely impact their respective businesses, CVS Health’s ability to complete the transaction and/or CVS Health’s ability to realize the expected benefits from the transaction. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on the transaction and/or CVS Health or Aetna, CVS Health’s ability to successfully complete the transaction and/or realize the expected benefits from the transaction. Additional information concerning these risks, uncertainties and assumptions can be found in CVS Health’s and Aetna’s respective filings with the SEC, including the risk factors discussed in “Item 1.A. Risk Factors” in CVS Health’s and Aetna’s most recent Annual Reports on Form 10-K, as updated by their Quarterly Reports on Form 10-Q and future filings with the SEC.

You are cautioned not to place undue reliance on CVS Health’s and Aetna’s forward-looking statements. These forward-looking statements are and will be based upon management’s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. Neither CVS Health nor Aetna assumes any duty to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, as of any future date.

GRAPHIC 2 g505652gra1.jpg GRAPHIC begin 644 g505652gra1.jpg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end GRAPHIC 3 g505652gra2.jpg GRAPHIC begin 644 g505652gra2.jpg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࿻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